<div id="readability-page-1"><p><span>Vor Biopharma (NASDAQ:VOR - Get Free Report)</span> had its price target reduced by equities research analysts at JPMorgan Chase &amp; Co.  from $43.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price objective points to a potential upside of 207.81% from the company's previous close.</p><div><p><span></span><span>Get <strong>Vor Biopharma</strong> alerts:</span></p></div><p>VOR has been the subject of several other research reports. HC Wainwright cut their price target on Vor Biopharma from $55.00 to $32.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, November 14th. Zacks Research upgraded shares of Vor Biopharma from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 11th. Wedbush assumed coverage on shares of Vor Biopharma in a research report on Tuesday, November 25th. They set a &#34;neutral&#34; rating for the company. Baird R W upgraded shares of Vor Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. One equities research analyst  has rated the stock with a Strong Buy rating, six have assigned  a Buy rating, five have given a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $68.43.</p><p><b>Check Out Our Latest Stock Report on VOR</b></p><h2>Vor Biopharma Price Performance</h2><p>Shares of VOR traded up $0.20 on Friday, reaching $13.00. The stock had a trading volume of 433,543 shares, compared to its average volume of 691,439. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The stock has a market cap of $135.28 million, a price-to-earnings ratio of -0.03 and a beta of 2.08. The company's 50-day moving average is $16.87. </p><h2>Insider Activity at Vor Biopharma</h2><p>In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 260,859 shares of the business's stock in a transaction on Friday, October 17th. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01. Following the completion of the transaction, the director directly owned 15,104 shares in the company, valued at approximately $443,906.56. The trade was a 94.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Reprogrammed Interchange Llc sold 75,262 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $33.87, for a total value of $2,549,123.94. Following the transaction, the insider directly owned 1,423,659 shares in the company, valued at approximately $48,219,330.33. This represents a 5.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,674,800 shares of company stock worth $49,516,960 in the last three months. Insiders own  0.45% of the company's stock. </p><h2>Institutional Investors Weigh In On Vor Biopharma</h2><p>Several large investors have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp purchased a new position in shares of  Vor Biopharma in the 1st quarter valued at $100,000.  Goldman Sachs Group Inc. raised its position in  Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares during the period.  Jane Street Group LLC acquired a new position in shares of  Vor Biopharma during the first quarter worth about $140,000.  XTX Topco Ltd acquired a new position in shares of  Vor Biopharma during the second quarter worth about $66,000.  Finally, Ariose Capital Management Ltd purchased a new stake in shares of  Vor Biopharma in the third quarter worth about $5,368,000. Institutional investors and hedge funds own  97.29% of the company's stock. </p><h2>Vor Biopharma Company Profile</h2> (Get Free Report)<p>Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Vor Biopharma</li><li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li><li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li><li>Upcoming IPO Stock Lockup Period, Explained</li><li>TL;DR: Why Reddit is the New Growth Stock to Beat</li><li>Options Trading - Understanding  Strike Price</li><li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Vk9S?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Vk9S"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vor Biopharma Right Now?</h2><p>Before you consider Vor Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.</p><p>While Vor Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>JPMorgan Chase & Co. lowered its price target for Vor Biopharma from $43.00 to $40.00, maintaining an "overweight" rating. Despite the reduction, the target suggests a potential upside of 207.81%. Other analysts have varied ratings, with a consensus of "Moderate Buy" and an average target price of $68.43. Vor Biopharma's stock traded at $13.00, with insider sales and institutional investments noted.</p>

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price